← Back to Clinical Trials
Recruiting Phase 3 NCT07413055

NCT07413055 Comparative Efficacy Of 4 mg VS. 8 mg Submucosal Dexamethasone In Postoperative Pain Management After Dental Implant Surgery: A Randomized Double-Blind Controlled Clinical Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07413055
Status Recruiting
Phase Phase 3
Sponsor Oman Ministry of Health
Condition Postoperative Pain
Study Type INTERVENTIONAL
Enrollment 138 participants
Start Date 2026-03-25
Primary Completion 2026-11-15

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Dexamethasone 4 Mg/mL Injectable SolutionDexamethasone 8Mg Solution for InjectionSaline (NaCl 0,9 %) (placebo)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.

This trial targets 138 participants in total. It began in 2026-03-25 with a primary completion date of 2026-11-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to compare the effectiveness of 4mg and 8mg dexamethasone administered submucosally in reducing postoperative pain after dental implant surgery. Participants will be randomly assigned to receive either 4mg dexamethasone, 8mg dexamethasone, or a placebo (normal saline) at the surgical site. Later, postoperative pain will be assessed using a Visual Analog Scale at 6 hours after the surgery and daily for the next 6 days. Also the number of pain-relief tablets consumed after the surgery will be recorded. Preoperative anxiety will be assessed using Generalized Anxiety Disorder-7 (GAD-7) questionnaire to assess its association with postoperative pain scores. The results of this study will help determine the optimal dose of dexamethasone that is effective for postoperative pain control following dental implant surgery.

Eligibility Criteria

Inclusion Criteria: * Males \& females * Age range (21-80) * ASA I \& II according to (American Society of Anesthesiologists) classification * Single tooth implant * Type 3 \& type 4 implant placement timing (Chen and Buser, 2009) Exclusion Criteria: * Any known allergy to any medications which will be used in the study * Smokers/ Alcoholics * Pregnant and lactating women * Bone augmentation/ sinus lifting required during the surgery * The need of antibiotic prophylaxis

Contact & Investigator

Central Contact

Shurooq Slim Al Hinai, BDS

✉ shurooqalhinai@gmail.com

📞 +968 96148103

Frequently Asked Questions

Who can join the NCT07413055 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, up to 80 Years, studying Postoperative Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT07413055 trial and what does that mean for participants?

Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 138 participants.

Is NCT07413055 currently recruiting?

Yes, NCT07413055 is actively recruiting participants. Contact the research team at shurooqalhinai@gmail.com for enrollment information.

Where is the NCT07413055 trial being conducted?

This trial is being conducted at Muscat, Oman.

Who is sponsoring the NCT07413055 clinical trial?

NCT07413055 is sponsored by Oman Ministry of Health. The trial plans to enroll 138 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology